Latest Healthcare Technology News

Page 1 of 17
Mach7 Technologies has signed Temple Health to a five-year licence for its eUnity Viewer and Vendor Neutral Archive, with Year 1 annual recurring revenue expected to reach A$0.5 million. The revenue will depend on go-live and first productive use, forecast within six to 12 months.
Victor Sage
Victor Sage
13 Nov 2026
Alcidion has entered FY27 with record contracted revenue, a debt-free balance sheet and reaffirmed guidance for revenue and underlying EBITDA to exceed FY26. Shareholders also approved a 10-for-1 share consolidation as the healthcare software company weighs buy-backs, acquisitions and further platform investment.
Victor Sage
Victor Sage
12 Nov 2026
Clever Culture Systems has secured $2.6 million to develop APAS Revolution, a smaller benchtop system aimed at pharmaceutical manufacturers not served by its existing platform. The funding combines a discounted share placement with new debt, while commercial launch is targeted for the first half of 2028.
Victor Sage
Victor Sage
3 Nov 2026
InteliCare ended the September quarter with A$1.394 million in cash after an operating cash outflow of A$1.271 million, leaving just 1.10 quarters of estimated funding. The company is relying on customer receipts from expanding deployments, while continuing to assess funding options.
Sophie Babbage
Sophie Babbage
30 Oct 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
Visionflex ended the September quarter with A$657,000 in cash and estimated funding for just 2.1 quarters, while aged care subscription losses drove a 25% fall in reported ARR. Revenue edged higher and costs improved, but the company now needs hardware wins to become recurring income before liquidity tightens further.
Victor Sage
Victor Sage
30 Oct 2026
Oakridge International reported a $267,000 operating cash outflow for the September quarter, leaving $343,000 in cash and an estimated 1.28 quarters of funding. The healthcare technology company expects collections and customer orders to improve cash flow, while evaluating additional funding and continuing to manage a potential historical claim from Teko International.
Victor Sage
Victor Sage
30 Oct 2026
HeraMED has moved its Lee Health digital maternity program from a six-month pilot into a paid deployment covering an initial 200 mothers. The milestone brings commercial revenue, but the company still faces a short cash runway as it works to scale the US rollout.
Victor Sage
Victor Sage
30 Oct 2026
Mach7 Technologies has completed a costly FY26 reset, cutting operating expenditure by 16% while revenue fell 17% and the net loss widened to A$8.9 million. The company enters FY27 with a higher recurring-revenue mix, new customer orders and A$19.9 million in cash, but no earnings guidance and plenty to prove.
Victor Sage
Victor Sage
30 Oct 2026
Vitasora Health has signed a Florida healthcare agreement covering an initially addressable 9,000 Medicare patients while estimated October billable care minutes rose 50%. The ASX-listed company also agreed terms for an A$3 million secured facility, but the funding is not yet drawn and carries approval, interest and dilution conditions.
Ada Torres
Ada Torres
30 Oct 2026
Enlitic’s Ensight platform reached approximately US$760,000 in annualised recurring revenue as two more US deployments went live and a US$806,000 University of Michigan migration project progressed. The company also ended the quarter with US$9.453 million in cash after completing its capital raise and converting its notes into equity.
Victor Sage
Victor Sage
29 Oct 2026
Alcidion has started FY27 with contracted revenue up 38% to $50.0 million, while a major UK expansion and new patient administration product widen its growth case. The company has also reaffirmed that FY27 revenue and underlying EBITDA will exceed FY26, but its capital plan now has several competing demands.
Victor Sage
Victor Sage
29 Oct 2026

Browse the archive

Full archive